Literature DB >> 7066165

The effect of activated dimethicone and a proprietary antacid preparation containing this agent on the absorption of phenytoin.

J C McElnay, G Uprichard, P S Collier.   

Abstract

1 The bioavailabilty of phenytoin sodium (Epanutin both alone and in combination with activated dimethicone and Asilone (a proprietary antacid preparation containing activated dimethicone) was examined in six healthy male volunteers. 2 The bioavailability of phenytoin when given concomitantly with Asilone was decreased in five of six volunteer subjects (by greater than 30% in three subjects) although this decrease was not shown to be statistically significant. 3 Dimethicone, which has been shown to decrease phenytoin absorption in vitro did not affect phenytoin bioavailability in vivo. 4 It is recommended that when treating patients stabilised on phenytoin one should exercise caution with concomitant phenytoin and antacid therapy to guard against possible changed drug absorption.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7066165      PMCID: PMC1402039          DOI: 10.1111/j.1365-2125.1982.tb01411.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  13 in total

1.  Effects of antacids on gastric emptying.

Authors:  A Hurwitz; R G Robinson; T S Vats; F C Whittier; W F Herrin
Journal:  Gastroenterology       Date:  1976-08       Impact factor: 22.682

2.  Plasma diphenylhydantoin levels in Australian adults.

Authors:  W D Hooper; J H Tyrer; M J Eadie
Journal:  Aust N Z J Med       Date:  1974-10

3.  Management of epilepsy with diphenylhydantoin sodium. Dosage regulation for problem patients.

Authors:  H Kutt; F McDowell
Journal:  JAMA       Date:  1968-03-11       Impact factor: 56.272

4.  Influences on the absorption of diphenylhydantoin preparations.

Authors:  A Windorfer; S Stünkel; H M Weimann
Journal:  Neuropadiatrie       Date:  1978-05

5.  Interaction between phenytoin and antacids.

Authors:  V K Kulshrestha; M Thomas; J Wadsworth; A Richens
Journal:  Br J Clin Pharmacol       Date:  1978-08       Impact factor: 4.335

6.  Failure of antacids to alter the pharmacokinetics of phenytoin.

Authors:  L S O'Brien; M L Orme; A M Breckenridge
Journal:  Br J Clin Pharmacol       Date:  1978-08       Impact factor: 4.335

7.  Pharmacokinetics of a single dose of phenytoin in man measured by radioimmunoassay.

Authors:  J D Robinson; B A Morris; G W Aherne; V Marks
Journal:  Br J Clin Pharmacol       Date:  1975-08       Impact factor: 4.335

8.  Interactions of antiepileptic drugs.

Authors:  H Kutt
Journal:  Epilepsia       Date:  1975-06       Impact factor: 5.864

9.  Individualization of phenytoin dosage regimens.

Authors:  T M Ludden; J P Allen; W A Valutsky; A V Vicuna; J M Nappi; S F Hoffman; J E Wallace; D Lalka; J L McNay
Journal:  Clin Pharmacol Ther       Date:  1977-03       Impact factor: 6.875

10.  The rate of decline of diphenylhydantoin in human plasma.

Authors:  K Arnold; N Gerber
Journal:  Clin Pharmacol Ther       Date:  1970 Jan-Feb       Impact factor: 6.903

View more
  1 in total

Review 1.  Pharmacokinetic drug interactions with phenytoin (Part II).

Authors:  R L Nation; A M Evans; R W Milne
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.